HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.
about
New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunityNew genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityEvolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Review of Toxic Epidermal NecrolysisSevere Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationProgress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityHuman leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.Pharmacogenomics of off-target adverse drug reactions.Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription.HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.T cell-mediated hypersensitivity reactions to drugsPharmGKB summary: very important pharmacogene information for human leukocyte antigen B.HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients.The HLA-A*31:01 allele: influence on carbamazepine treatmentThe emerging era of pharmacogenomics: current successes, future potential, and challenges.Personalized medicine approaches in epilepsy.Role of dermatology in pharmacogenomics: drug-induced skin injury.Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.The pharmacogenomics of epilepsy.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.Recent advances in the understanding of severe cutaneous adverse reactions.The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibilityIn vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.A novel multiplex PCR assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese.Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study.Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature.HLAs: Key regulators of T-cell-mediated drug hypersensitivity.HLA Association with Drug-Induced Adverse Reactions.Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking.Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome.
P2860
Q26800973-16CB79B5-3C5E-42EB-8A31-0E1CA883D980Q26800976-4BE245F6-5123-4159-8928-1FC190A5DE58Q26800980-541EE38D-30E5-4468-A8BB-20DC984982DFQ28074097-43AB544B-3B47-4FEA-B903-9D694A04C70AQ28076600-A6676C5C-2742-46FF-BA94-1A507E86766AQ28083100-42A31AEF-17CF-47D4-AAA5-8FBBE3C7772BQ30238992-8D13B973-6502-4949-A9E4-7C0823F2307CQ30400366-336196F0-E9DE-4A3A-A783-F0B81C038963Q33572210-7B7955D7-D2B6-406C-901A-80F3B97B0204Q33666857-237E6986-0D72-47BE-AFC1-A02FD3274FD7Q34557668-88D7C723-4410-4744-93BE-28BD5261B9E1Q34971993-C6CC5CDB-0EF2-416A-9FB6-2008EF04C330Q35168561-1039F66B-228F-4D8A-8E08-317D2D2BB353Q36418662-4AFD6C4F-CC18-4D10-9D97-A5635608BC75Q37548990-74948134-A596-4E38-A6DF-0507DBEE680CQ37626751-B35A1DF3-57DB-4F6D-92A2-F71C3ECA2837Q38200683-2D9EF5E2-A9E9-4C7E-8ADC-BBD397FB8A01Q38262011-577872EE-2B42-4498-9F53-21DCC8643D57Q38396234-5F8C59D5-7675-4784-82F8-94FB5391AA17Q38457053-8B7DF7B5-E00C-4062-9489-749486F726FEQ38577986-5AA92CBE-C206-4085-BCA4-CCA66E7056BAQ38611191-4D2DD031-5976-4AA2-8D85-C1C0C6C5EC68Q38629821-4244E760-8C41-4A4F-85B1-0F0C746CE327Q38931289-9DD1E39C-3CD9-4E1A-82E3-33AD2078EE1FQ39427540-BAE99E40-0286-4758-A79C-90CE64FF98EDQ39555733-6D0815FF-F66A-49AB-AFCD-C80D73A37047Q39909074-07EC06AD-209A-418F-835C-D2536DC5D6C2Q40051391-E83D4F2A-243D-44A9-A97A-9C2561AC7AA0Q40405160-41AD596E-FB8B-4476-972D-6F5D55AEF0A4Q42072504-43BE41D0-302F-417E-8F7E-4416642F29C9Q42281124-31C36437-5368-43F5-8B26-D11018CF088CQ47320133-1BF4EB86-2F96-473E-AA2C-EBC626AE3EADQ47553722-6508EA0B-57CD-42F2-9D3D-329E59FCEAE9Q47703247-33D85776-E42B-4BC6-B0F2-38E4E4243926Q48861311-926D0B5C-5B70-493A-9173-1CFA4C2AE651Q50115047-4570F2DB-FF57-4188-AFC0-74C22897B814Q52702236-58137AC0-8691-42D2-A92A-84F7445BEE9EQ52719665-40759B30-C5CE-4DEB-9315-F761C843A0D0Q53782592-514FE7E6-FA1F-47DB-9D4A-243AA22E2321Q53801531-284270B3-8B43-4F2B-9D09-97930BC2471D
P2860
HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
HLA-A*31:01 and different type ...... ional study and meta-analysis.
@en
HLA-A*31:01 and different type ...... ional study and meta-analysis.
@nl
type
label
HLA-A*31:01 and different type ...... ional study and meta-analysis.
@en
HLA-A*31:01 and different type ...... ional study and meta-analysis.
@nl
prefLabel
HLA-A*31:01 and different type ...... ional study and meta-analysis.
@en
HLA-A*31:01 and different type ...... ional study and meta-analysis.
@nl
P2093
P2860
P50
P356
P1476
HLA-A*31:01 and different type ...... tional study and meta-analysis
@en
P2093
J-C Roujeau
M Mockenhaupt
M Schumacher
P Wolkenstein
P2860
P2888
P304
P356
10.1038/TPJ.2013.40
P577
2013-12-10T00:00:00Z